Work

Long-acting preparations of exenatide

Year: 2013
Type: review
Abstract: : Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations. Keywords: exendin-4, diabetes mellitus type 2, sustained release, long acting, extended release, microsphere
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2157365347
FWCI: 0.301
Cites: 66
Cited by: 69
Related to: 10